Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Vevesca regulatory update

OGS received a non-approvable letter from the FDA for its Vevesca to treat Gaucher disease. According to OGS, FDA said there was not sufficient support for the safety and efficacy

Read the full 306 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE